Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB)
CUSIP: 29405E505
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 1,414,064
- Total 13F shares
- 24,171
- Share change
- +24,171
- Total reported value
- $87,744
- Price per share
- $3.63
- Number of holders
- 11
- Value change
- +$87,744
- Number of buys
- 11
Quarterly Holders Quick Answers
What is CUSIP 29405E505?
CUSIP 29405E505 identifies ENVB - Enveric Biosciences, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Recent filing periods for CUSIP 29405E505:
Top shareholders of ENVB - Enveric Biosciences, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| AdvisorShares Investments LLC |
13F
|
Company |
9.8%
|
203,679
|
$130,232 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
5.1%
|
105,333
|
$67,309 | — | 30 Sep 2025 | |
| Joseph Edward Tucker |
3/4/5
|
Chief Executive Officer, Director |
3.4%
|
70,355
|
$42,916 | — | 23 Dec 2025 | |
| Orca Capital AG |
13D/G
|
— |
4.9%
|
97,019
|
$32,016 | -$22,984 | 31 Jan 2025 | |
| Kevin Michael Coveney |
3/4/5
|
Chief Financial Officer |
2.3%
|
47,413
|
$28,921 | — | 23 Dec 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
0.4%
|
19,333
|
$28,033 | -$122,696 | 18 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
28,510
|
$18,229 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.1%
|
22,674
|
$14,498 | — | 30 Sep 2025 | |
| Peter J. Facchini |
3/4/5
|
CHIEF INNOVATION OFFICER |
3.2%
|
33,058
|
$10,909 | — | 08 May 2025 | |
| AdvisorShares Trust |
13D/G
|
— |
1.7%
|
16,974
|
$5,601 | -$61,613 | 31 Dec 2025 | |
| Frank Pasqualone |
3/4/5
|
Director |
0.38%
|
7,904
|
$4,821 | — | 23 Dec 2025 | |
| George A. Kegler |
3/4/5
|
Director |
0.38%
|
7,900
|
$4,819 | — | 23 Dec 2025 | |
| Marcus Schabacker |
3/4/5
|
Director |
0.38%
|
7,900
|
$4,819 | — | 23 Dec 2025 | |
| Michael D. Webb |
3/4/5
|
Director |
0.38%
|
7,898
|
$4,817 | — | 23 Dec 2025 | |
| Sheila DeWitt |
3/4/5
|
Director |
0.37%
|
7,788
|
$4,750 | — | 23 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.12%
|
2,418
|
$1,546 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.03%
|
601
|
$384 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.03%
|
600
|
$384 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
26
|
$17 | — | 30 Sep 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0%
|
5
|
$3 | — | 30 Sep 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
2
|
$1 | — | 30 Sep 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| Carter Julian Ward |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
744,429
|
— | — | 19 Jan 2022 | |
| Ayrton Capital LLC |
13D/G
|
— |
10%
|
658,465
|
— | $0 | 30 Sep 2025 | |
| Thompson Bradley George |
3/4/5
|
Director |
—
class O/S missing
|
53,160
|
— | — | 16 Sep 2021 | |
| Avani Kanubaddi |
3/4/5
|
President and COO |
—
class O/S missing
|
48,346
|
— | — | 25 Jan 2023 | |
| Jillian Marie Hagel |
3/4/5
|
Vice President of Innovation |
—
class O/S missing
|
35,802
|
— | — | 25 Jan 2023 |
Institutional Holders of Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB) as of Q4 2025
As of 31 Dec 2025,
Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,171 shares.
The largest 10 holders included
AdvisorShares Investments LLC, UBS Group AG, CITIGROUP INC, Tower Research Capital LLC (TRC), BlackRock, Inc., SBI Securities Co., Ltd., BANK OF AMERICA CORP /DE/, DANSKE BANK A/S, GROUP ONE TRADING LLC, and WELLS FARGO & COMPANY/MN.
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
0
Q4 2025 holders
11
Holder diff
11
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.